Find Funding

Contract Topics

275 Development of Generic Antibodies for the Treatment of Cancer

Number of anticipated awards: 3

(Fast-Track proposals will NOT be accepted. Phase II information is provided only for informational purposes to assist Phase I proposers with their long-term strategic planning.)

Budget (total costs): Phase I: $300,000;
Phase II: $2,500,000

(Note: It is strongly suggested that Proposals adhere to the above budget amounts. Proposals with budgets exceeding the above amounts may not be funded. Phase I project periods may last a maximum of 9 months.)

The deadline for receipt of all contract proposals submitted in response to this solicitation is: November 9, 2009.

Summary:
New biological agents for the treatment of cancer are steadily entering the market. These targeted biologics carry the hope of ushering in the next generation of cancer therapy. Yet, there are often toxicities associated with them and they are very expensive, costing more than $100,000 per year to administer. The overall goal of this SBIR contract topic is to support small businesses to develop generic and lower priced versions of therapeutic biologics for the treatment of cancer.

Project Goals:
The goal of the NCI SBIR program is to accelerate the development of products that benefit cancer patients. As such, the short-term goal of this project is to stimulate the development of biosimilars for cancer therapy, whereas its long-term objective is the enhancement of competition in the biologics arena in order to reduce the cost of therapy for this class of molecules. The long-term goal would be the commercialization of generic versions of therapeutic antibodies for the treatment of various cancers.